Close Menu

NEW YORK – Prometheus Biosciences announced on Friday that it has priced its upsized initial public offering of 10 million shares of common stock at $19 per share.

The shares are expected to start trading on the Nasdaq on March 12 under ticker symbol RXDX. Prometheus expects gross proceeds from the offering, expected to close on March 16, to be $190 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.